IDYA vs TNGX
IDYA: IDEAYA is a precision oncology company leveraging tumor genetics and DNA damage response pathways to develop targeted cancer therapies, with multiple clinical-stage candidates supported by collaborations with major pharma partners. TNGX: A precision oncology company utilizing a proprietary functional genomics platform to discover and develop targeted, synthetic-lethal cancer therapies.
Side-by-side fundamentals
| Metric | IDYA | TNGX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $35.00 | $28.10 | |
| Market cap as of 2026-07-23 | $3.3B | $4.6B | |
| Net margin as of 2026-07-23 | -27.8% | -151.2% | IDYA higher |
| Operating margin as of 2026-07-23 | -42.0% | -165.9% | IDYA higher |
| ROE as of 2026-07-23 | -13.9% | -41.5% | IDYA higher |
| ROA as of 2026-07-23 | -12.8% | -33.4% | IDYA higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | +3118.1% | +39.0% | IDYA higher |
| Revenue CAGR (3y) SEC XBRL | +62.5% | +35.9% | IDYA higher |
| Beta as of 2026-07-23 | -0.10 | 1.12 | |
| 1-year return as of 2026-07-22 close | +65.0% | +328.7% | TNGX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.